TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19849996
Drug: Intradermal trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal trivalent inactivated seasonal influenza vaccine (15 microg of haemagglutinin per strain per 0.1 ml dose)
Study: 19849996
Drug: Intradermal trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal trivalent inactivated seasonal influenza vaccine
Study: 19849996
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular vaccine
Study: 15315995
Drug: Fluoxetine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine with CBT (10 to 40 mg/d)
Study: 15315995
Drug: Fluoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine alone (10 to 40 mg/d)
Study: 15315995
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent to 10 to 40 mg/d)
Study: 15315995
Drug: Fluoxetine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine with CBT
Study: 11699608
Drug: E 5
Normalized name: Fe 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E 5 mg (intranasal)
Study: 11699608
Drug: E 10
Normalized name: RE 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: E 10 mg (intranasal)
Study: 11699608
Drug: E 50
Normalized name: Fe 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E 50 mg (oral)
Study: 9814459
Drug: Standardized regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized regimen of calcium supplements and phosphorus binders, no vitamin D derivatives
Study: 7640329
Drug: m-CPP (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP (0.1 mg/kg) in untreated conditions
Study: 9107154
Drug: Light treatment
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light treatment
Study: 2752859
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment without preoperative measures
Study: 593989
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of indomethacin
Study: 29196479
Drug: Digital cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive-behavioural therapy for insomnia (CBT-I) for 6 weeks
Study: 26485217
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IU orally once weekly for 8 weeks)
Study: 26485217
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo once weekly for 8 weeks)
Study: 21741720
Drug: Concurrent re‐irradiation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent re‐irradiation, fluorouracil and hydroxyurea (R‐RT)
Study: 2012354
Drug: Ciprofloxacin plus
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin plus loperamide (4 mg first dose, 2 mg for every loose stool, max 16 mg/d)
Study: 29499208
Drug: Water vapor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water vapor thermal therapy (Rezūm® System)
Study: 29499208
Drug: Any medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any medical therapy (doxazosin and/or finasteride)
Study: 19087695
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao capsules, orally 4 days before operation once daily and then via nasal feeding tube after operation once a day for 5 days
Study: 16153398
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg mosapride (3 times daily for 5 days)
Study: 16153398
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg administered after morphine)
Study: 16153398
Drug: Mosapride in
Normalized name: Product containing mosapride in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride in rats (100 mg/kg orally)
Study: 1932450
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination with 4 x 100 g polymyxin E, 4 x 80 mg tobramycin and 4 x 500 mg amphotericin B administered through the gastric tube and with an antimicrobial sticky paste in the oropharynx (group I)
Study: 1932450
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of polymyxin B and 80 mg of gentamicin dissolved in 10 ml of 0.9% saline at 6 h intervals into nose, oropharynx and stomach as well as 300 mg of amphotericin B in the oropharynx only (group II)
Study: 26434665
Drug: Lantus® insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lantus® insulin glargine (IGlar)
Study: 21960113
Drug: Truncal/chest/arm advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truncal/chest/arm advanced pneumatic compression therapy
Study: 2010437
Drug: Aspirin (85‐325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (85‐325 mg daily up to or within 48 hours of surgery)
Study: 2010437
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (discontinued at least 4 days before surgery)
Study: 7104563
Drug: Paracetamol/dextropropoxyphene (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/dextropropoxyphene (control)
Study: 29556866
Drug: AZD5672 (experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5672 (experimental compound)
Study: 24332324
Drug: Preemptive lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive lornoxicam 8 mg intravenously 25 minutes before surgery
Study: 17115388
Drug: Immediate-release levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate-release levodopa (IR LD)
Study: 17115388
Drug: Controlled-release levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release levodopa (not specified if used in this context)
Study: 15625351
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium 1000 mg/day
Study: 12212876
Drug: Warmed local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed local anesthetic solution (37 degrees C)
Study: 12212876
Drug: Room-temperature local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Room-temperature local anesthetic solution (21 degrees C)
Study: 7780131
Drug: rBPI23 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI23 (1 mg/kg)
Study: 8597874
Drug: Placebo (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (human serum albumin, 0.2 mg/kg)
Study: 22686269
Drug: Risk Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk Reduction through Family Therapy (RRFT)
Study: 30253725
Drug: Intensive pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive pharmacist intervention at the beginning of oral antineoplastic therapy
Study: 24856027
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid administration protocol (Control group, n=200)
Study: 16631046
Drug: Perioperative topical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative topical levofloxacin
Study: 7910321
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (mitomycin, doxorubicin, and fluorouracil)
Study: 3213065
Drug: Doxium (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxium (calcium dobesilate) 1000 mg (2 x 1 capsule) daily for 8 weeks (2 weeks preoperatively and 6 weeks postoperatively)
Study: 30945151
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 500 mg once daily for 6 months postoperatively
Study: 28532702
Drug: Trimetazidine 35
Normalized name: trimetazidine 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35 mg twice daily for 72 hours, starting 48 hours before the procedure, in addition to isotonic saline hydration.
Study: 28532702
Drug: Trimetazidine 35
Normalized name: trimetazidine 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35 mg twice daily for 72 hours, starting 48 hours before the procedure, in conjunction with isotonic saline hydration.
Study: 27883324
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (50 μg transdermal oestradiol, 5 mg MPA)
Study: 20671103
Drug: Conventional glucose-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose-containing dialysis solution (group A)
Study: 15603207
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg
Study: 11282902
Drug: Low-dose sibrafiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sibrafiban plus aspirin (LDS+A)
Study: 11282902
Drug: High-dose sibrafiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sibrafiban (HDS)
Study: 8777774
Drug: Dextromethorphan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (1.5 mg/kg)
Study: 6386897
Drug: Folate mouthwash
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate mouthwash (5 ml twice daily for 4 weeks, containing 5 mg folate per 5 ml)
Study: 28419379
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic to a peripheral pain generator (MTrP or other discrete tender point)
Study: 28419379
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic
Study: 16796730
Drug: WS 5570
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 5570 600 mg/day
Study: 16796730
Drug: WS 5570
Approvals — FDA: no, EMA: no, PMDA: no
Description: WS 5570 1200 mg/day
Study: 11423999
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 microg/kg/d) after PBPC transplantation at day 1
Study: 11423999
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF administration
Study: 11423999
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of > 5 x 10(6)/kg CD34+ cells
Study: 11423999
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ≤ 5 x 10(6)/kg CD34+ cells
Study: 23422652
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration
Study: 8873964
Drug: Supervised, non-strenuous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised, non-strenuous, weight-lifting exercise program (performed once a week at the medical facility and twice a week on their own)
Study: 1099948
Drug: Inhaled atropine
Normalized name: atropine sulfate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled atropine sulfate
Study: 769527
Drug: Spironolactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (200 mg/day for 2 months)
Study: 769527
Drug: Propranolol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (320 mg/day for 2 months)
Study: 769527
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of spironolactone and propranolol at half dosage
Study: 16813590
Drug: Laparoscopic rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic rectal cancer surgery
Study: 21160307
Drug: Open rectal
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open rectal cancer surgery
Study: 14752411
Drug: 20 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ppm of inhaled nitric oxide
Study: 14752411
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional inhalatory treatment
Study: 9206771
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate 5 mg daily per os
Study: 9206771
Drug: Didrogesteron 10
Normalized name: Didrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didrogesteron 10 mg twice a day per os
Study: 8320052
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement taken daily for 4 months
Study: 8320052
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken daily for 4 months
Study: 17209217
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement
Study: 29926912
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 and 0.2 μg/kg/min)
Study: 29926912
Drug: Milrinone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (0.4 and 0.8 μg/kg/min)
Study: 25816046
Drug: Religiously integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Religiously integrated cognitive behavioral therapy (RCBT)
Study: 25816046
Drug: Conventional cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cognitive behavioral therapy (CCBT)
Study: 27305903
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in DSE with treatment
Study: 20665514
Drug: IGIV-C (Gamunex)
Normalized name: Gamunex
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (Gamunex) administered every 3 weeks for up to 24 weeks
Study: 20665514
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 3 weeks for up to 24 weeks
Study: 10726441
Drug: Transdermal hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormonal therapy with 50 micrograms of ethynilestradiol and 5 mg of MAP
Study: 7718318
Drug: Melphalan 15
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 15 mg/m2 intravenously (i.v.) and prednisone 60 mg/m2 oral days 1‐4 (MP)
Study: 7718318
Drug: IFN‐alpha (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha (5 x 10(6) IU, subcutaneous (S.C.) 3 times per week)
Study: 1818628
Drug: Therapeutic concept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic concept including effective motivation; specific details on dosage and duration not available.
Study: 7445641
Drug: Urografin 76%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urografin 76% with added calcium (22.5 mEq/l)
Study: 7445641
Drug: Urografin 76%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urografin 76% with added calcium (33.75 mEq/l)
Study: 25887469
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of glucocorticoids
Study: 17729399
Drug: Kiwifruit (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kiwifruit (twice daily for 4 weeks)
Study: 15056829
Drug: Quinapril 10
Normalized name: quinapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 10 mg/day
Study: 12233807
Drug: Leech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leech therapy (4 leeches applied topically at painful periarticular sites)
Study: 12233807
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for pain (excluding nonsteroidal anti-inflammatory drugs)
Study: 8010369
Drug: Alternating time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating time schedule of bright light treatment
Study: 8010369
Drug: Fixed morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed morning schedule of bright light treatment
Study: 8010369
Drug: Fixed evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed evening schedule of bright light treatment
Study: 2671449
Drug: Nisoldipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (2.5 mg once a day, increased to 5-10 mg per day for 12 weeks)
Study: 25415245
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) + Scaling and Root Planing (SRP)
Study: 23233423
Drug: Automated framework
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated framework for identifying medication overuse
Study: 18280939
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline solution (Ss)
Study: 9132505
Drug: Caffeine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (125 mg)
Study: 2947953
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms hepatitis B vaccine
Study: 1535229
Drug: 2 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms hepatitis B vaccine
Study: 1535229
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram hepatitis B vaccine
Study: 1535229
Drug: Low anti-HBs
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low anti-HBs titres (10-100 miu/mL)
Study: 1535229
Drug: Medium anti-HBs
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium anti-HBs titres (101-1000 miu/mL)
Study: 1535229
Drug: High anti-HBs
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High anti-HBs levels (greater than 1000 miu/mL)
Study: 6707051
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g gentamicin base per 40 g pack of powdered polymer
Study: 6707051
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g gentamicin base per 40 g pack of powdered polymer
Study: 22675960
Drug: alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 10 microg/kg IV with propofol 0.7 mg/kg IV
Study: 22675960
Drug: ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 0.5 mg/kg IV with propofol 0.7 mg/kg IV
Study: 20367516
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy (6 sessions, once weekly for 30 min over 6-8 weeks)
Study: 18586313
Drug: Current hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current hormone therapy use
Study: 8446743
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, 5.4 ml/hr)
Study: 3011834
Drug: T4 treatment
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 treatment group (L-T4 1.5 micrograms/kg iv daily for 2 weeks)
Study: 3011834
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no T4 treatment)
Study: 27641143
Drug: Romosozumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (210 mg subcutaneous injections monthly for 12 months)
Study: 27641143
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injections monthly for 12 months)
Study: 20492573
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal soluble film (800 microg) administered as a single film
Study: 20492573
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal soluble film (200 microg) administered as four separate films simultaneously
Study: 20492573
Drug: Injectable fentanyl
Normalized name: fentanyl Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable fentanyl citrate (200 microg) administered by intravenous infusion
Study: 20492573
Drug: Injectable fentanyl
Normalized name: fentanyl Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable fentanyl citrate (800 microg/16 mL) administered orally
Study: 10520076
Drug: Active grass
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active grass pollen immunotherapy
Study: 8904617
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg LY293111 three times daily for 8 days
Study: 8904617
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg LY293111 three times daily for 8 days
Study: 8904617
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LY293111 twice daily for 8 days
Study: 6394044
Drug: Experiential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential treatment
Study: 6394044
Drug: Didactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didactic treatment
Study: 6394044
Drug: Non-conscious treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-conscious treatment
Study: 26887958
Drug: Antenatal depression-oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal depression-oriented acupuncture (weekly 1-hour treatments for 8 weeks from 24 to 31 weeks of gestation)
Study: 24804638
Drug: Embrace Advanced
Normalized name: Zembrace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embrace Advanced Scar Therapy device
Study: 20228401
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy targeting systolic pressure <120 mm Hg
Study: 20228401
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy targeting systolic pressure <140 mm Hg
Study: 7033015
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg suppository
Study: 6991534
Drug: Aspirin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1000 mg)
Study: 12188410
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract spray (111 mg)